Evidence map›Paper›PMID 38534542›Full record

ArticleBioengineering (Basel, Switzerland)2024

Seed Train Optimization in Microcarrier-Based Cell Culture Post In Situ Cell Detachment through Scale-Down Hybrid Modeling.

Atefeh Ebrahimian, Mona Schalk, Mark Dürkop, Michael Maurer, Rudolf Bliem, Harald Kühnel

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Bioprocess Engineering for Cultivated Meat.Advances in biochemical engineering/biotechnology · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Atefeh EbrahimianACIB-Austrian Centre of Industrial Biotechnology, Krenngasse 37, 8010 Graz, Austria.ORCID 0009-0004-5334-981X
Mona SchalkACIB-Austrian Centre of Industrial Biotechnology, Krenngasse 37, 8010 Graz, Austria.
Mark DürkopNovasign GmbH, 1020 Vienna, Austria.ORCID 0000-0003-4750-6474
Michael MaurerDepartment of Applied Life Science, Bioengineering, FH-Campus Wien, 1100 Vienna, Austria.ORCID 0000-0003-1316-0903
Rudolf BliemDepartment of Applied Life Science, Bioengineering, FH-Campus Wien, 1100 Vienna, Austria.
Harald KühnelDepartment of Applied Life Science, Bioengineering, FH-Campus Wien, 1100 Vienna, Austria.ORCID 0000-0002-4780-8061

Funding

Austrian Research Promotion Agency 19214426
6 · The paper itself

Abstract

Microcarrier-based cell culture is a commonly used method to facilitate the growth of anchorage-dependent cells like MA 104 for antigen manufacturing. However, conventionally, static cell culture is employed for cell propagation before seeding the production bioreactor with microcarriers (MCs). This study demonstrates the effective replacement of the conventional method by serial subculturing on MCs with in situ cell detachment under optimal conditions in closed culture units. This study proves that MA 104 can be subcultured at least five times on Cytodex 1 MC without the need for separating cells and MC after cell harvest. Process parameters impacting cell growth were studied post in situ cell detachment in a scaled-down model. Optimization, using augmented Design of Experiments (DoE) combined with hybrid modeling, facilitated rapid screening of the design space for critical process parameters (CPPs). Optimized conditions included an inoculation density of >16 cells/bead, 3.5-4.5 g/L of Cytodex 1, and a controlled agitation speed, starting at N

Indexed as

hybrid modelingin situ cell detachmentMA 104 cellsmicrocarrier cultureprocess optimizationseed training

Identifiers

PMID38534542
PMCPMC10968011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.